ArticleFrontiers in medicine2025
Burden of chronic obstructive pulmonary disease and its attributable risk factors in China from 1990 to 2021, with projections to 2050: an analysis of data from the Global Burden of Disease study 2021.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The patient-level economic burden of COPD in China: a systematic review of determinants and consequences.Frontiers in public health · 2026Pooled it
- Pharmacokinetics, Safety and Tolerability of HPP737, a Novel PDE4 Inhibitor, in Healthy Chinese Participants: Phase I Study.Drug design, development and therapy · 2026Trial
- Fabrication of Budesonide-Encapsulated β-Glucan Nanoparticles for Alleviation of Acute Bronchial Asthma via Modulation of the p38 MAPK Signaling Pathway.Applied biochemistry and biotechnology · 2026Article
- COPD burden trends in China and G20 countries from GBD 2023 and Mendelian randomization.iScience · 2026Article
- Application of the PDCA Cycle to Improve Quality Control in Pulmonary Function Testing for Early Screening of Chronic Obstructive Pulmonary Disease.The clinical respiratory journal · 2026Article
- Article
- Navigating complexity: nurses' experiences in delivering holistic care to patients with chronic obstructive pulmonary disease.BMC nursing · 2026Article
- Nonlinear association between P-wave axis and lung function in adult population with COPD: evidence from a cross-sectional study.Frontiers in medicine · 2026Article
- Article
- Ironing out COPD: ferroptosis-driven immune dysregulation, metabolic rewiring, and precision therapeutic opportunities.Frontiers in immunology · 2026Review
- Correlation between anemia-related red blood cell parameters and pulmonary function severity in patients with AECOPD.Frontiers in medicine · 2026Article
- The prevalence of chronic obstructive pulmonary disease in high-altitude areas of China: a systematic review and meta-analysis.Journal of thoracic disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) has become the third leading cause of death worldwide. This disease not only results in high mortality rates but also triggers substantial medical expenditures, significant loss of labor productivity, and a marked decline in patients' quality of life. Despite its severity, COPD is a preventable condition and has now emerged as a significant public health burden that cannot be overlooked. This study aimed to assess the burden of COPD and its attributable risk factors from 1990 to 2021 and to project trends through 2050, to provide an evidence basis for the development of a comprehensive COPD prevention and treatment strategy in China. Methods: Data were extracted from the Global Burden of Disease (GBD) 2021 study, including COPD-related incidence, prevalence, mortality, and disability-adjusted life years (DALYs). Age-standardized rates (ASRs) were calculated, and temporal trends were analyzed using estimated annual percentage change (EAPC) through linear regression modeling. A Bayesian age-period-cohort (BAPC) model was used to forecast trends up to 2050. Results: In 2021, China recorded 50.6 million prevalent COPD cases, 4.4 million incident cases, 1.29 million deaths, and 23.6 million DALYs. Between 1990 and 2021, the age-standardized incidence rate (ASIR) declined from 271.2 to 215.6 per 100,000 population; the age-standardized prevalence rate (ASPR) from 2,761.8 to 2,499.4 per 100,000; age-standardized mortality rate (ASMR) from 231.8 to 73.2 per 100,000; and age-standardized DALYs (ASDALYs) from 3,852.6 to 1,227.7 per 100,000. These reflect relative reductions of 20.5, 9.5, 68.4, and 68.1%, respectively. Conclusion: Despite substantial reductions in the COPD burden over the past three decades, the disease continues to pose a major health challenge in China, particularly among the aging population. Projections to 2050 indicate continued, though uneven, declines. These findings underscore the urgent need for strengthened diagnostic capacity, risk-targeted prevention efforts, and more effective long-term management strategies tailored to China's aging population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.